Stuart Lind, MD

Professor, Medicine-Medical Oncology


FacultyPhoto
Medical School
  • MD, New York University School of Medicine (1976)
Undergraduate School
  • AB, Cornell University (NY) (1972)
Internship
  • University of Chicago/Northwestern University Program (1977)
Residency
  • University of Chicago/Northwestern University Program, Chief Resident, Internal Medicine (1979)
Fellowships
  • Brigham and Women's Hospital/Massachusetts General Hospital Program, Hematology and Oncology (1981)
  • University of Colorado, Blood Banking / Transfusion Medicine (2007)
Languages
English
Department
Medicine-Medical Oncology

Publications

  • Lind SE. “The bleeding time” in Platelets, 2nd edition, Michelson AD (editor) Academic Press, Amsterdam, 2006.
  • 59. Prodan CI, Bottomley SS, Holland NR, Lind SE. Relapsing hypocupremic myelopathy requiring high dose oral copper replacement. Journal of Neurology, Neurosurgery & Psychiatry.77:1092-1093, 2006
  • 60. Ding WQ, Liu B, Vaught JL, Palmiter RD, Lind SE. Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Molecular Cancer Therapeutics.5:1864-1872, 2006.
  • 61. Prodan CI, Bottomley SS, Vincent AS, Cowan LD, Holland NR, Lind SE. Hypocupremia associated with prior vitamin B12 deficiency" Amer J. Hematology. In press.
  • Prodan CI, Bottomley SS, Vincent AS, Cowan LD, Holland NR, Lind SE. Hypocupremia associated with prior vitamin B12 deficiency" Amer. J. Hematology. 82:288-290, 2007.
  • Ding WQ, Lind SE. Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid-induced cytotoxicity. Molecular Cancer Therapeutics. 6:1467-1474, 2007.
  • Ding WQ, Yu H, Lind SE. Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Letters 271: 251-259, 2008
  • Yu H, Zhou Y, Lind SE, Ding WQ. Clioquinol targets zinc to lysosomes in human cancer cells. Biochem. J. 417:133-139, 2009.
  • Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle – in press
  • Yu H, Zhou Y, Lind SE, Ding WQ. Clioquinol targets zinc to lysosomes in human cancer cells. Biochem. J. 417:133-139, 2009.
  • Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909-915, 2009.
  • Prodan CI, Bottomley SS, Vincent AS, Cowan LD, Greenwood-Van Meerveld B, Holland NR, Lind SE. Copper deficiency after gastric surgery: a reason for caution. Am J Med Sci 337:256-258, 2009.
  • Bolin L, Fan, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8:2031-40, 2009.
  • Lind SE, Park JS, Drexler JW. Pyrithione and 8-hydroxyquinolines transport lead across erythrocyte membranes. Translational Research 154:153-159, 2009.
  • Ding WQ, Lind SE. Metal ionophores - an emerging class of anticancer drugs. IUBMB Life 61:1013-1018, 2009.
  • Zhang X, Yu, H, Lou JR, Zheng J, Zhu H, Popescu NI, Lupu F, Lind SE, Ding WQ. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 286:1429-1435, 2011.
  • Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. 10:2959-2966, 2011.
  • Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, Ding WQ. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett. 312:11-7, 2011.
  • Deng X-S, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple negative breast cancers. Cell Cycle 11:367-376,2012.
  • Deng X-S, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple negative breast cancers. Cell Cycle Cell Cycle. 11:367-376, 2012.
  • Zheng J, Payne K, Taggart JE, Jiang H, Lind SE, Ding WQ. Trolox enhances curcumin's cytotoxicity through induction of oxidative stress. Cell Physiol Biochem. 29:353-360, 2012.
  • Zhou J, Zhang S, Xue J, Avery J, Wu J, Lind SE, Ding WQ. Activation of peroxisome proliferator-activated receptor a (PPARa) suppresses hypoxia-inducible factor-1a (HIF-1a) signaling in cancer cells. J Biol Chem. 287:35161-35169, 2012.
  • Wang S, Avery JE, Hannafon BN, Lind SE, Ding WQ. Zinc protoporphyrin suppresses cancer cell viability through a heme oxygenase-1-independent mechanism: the involvement of the Wnt/ß-catenin signaling pathway. Biochem Pharmacol. 2013 Jun 1;85(11):1611-8. PubMed PMID: 23523860
  • Lind SE, Boyle ME, Fisher S, Ishimoto J, Trujillo TC, Kiser TH. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol. 2014 May;141(5):665-74. PubMed PMID: 24713737
  • Wang S, Hannafon BN, Wolf RF, Zhou J, Avery JE, Wu J, Lind SE, Ding WQ. Characterization of docosahexaenoic acid (DHA)-induced heme oxygenase-1 (HO-1) expression in human cancer cells: the importance of enhanced BTB and CNC homology 1 (Bach1) degradation. J Nutr Biochem. 2014 May;25(5):515-25. PubMed PMID: 24613086
  • Wang S, Hannafon BN, Lind SE, Ding WQ. Zinc Protoporphyrin Suppresses ß-Catenin Protein Expression in Human Cancer Cells: The Potential Involvement of Lysosome-Mediated Degradation. PLoS One. 2015;10(5):e0127413. PubMed PMID: 26000787
  • Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clin Appl Thromb Hemost. 2016 Jul;22(5):423-8. PubMed PMID: 26842561
  • Vanderbilt CM, McFarland C, Lind SE. Evaluation of a Reflex Testing Algorithm for Suspected Heparin-Induced Thrombocytopenia. Am J Clin Pathol. 2017 Nov 2;148(5):390-397. PubMed PMID: 29059268
  • McFarland CP, Lind SE. Thrombin Generation Biomarkers Decline With Parenteral Anticoagulation-An Overlooked Means of Anticoagulation Monitoring?. Clin Appl Thromb Hemost. 2018 Jul;24(5):708-717. PubMed PMID: 29439639
  • Beyer JT, Lind SE, Fisher S, Trujillo TC, Wempe MF, Kiser TH. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. J Thromb Thrombolysis. 2019 Sep 26. [Epub ahead of print] PubMed PMID: 31559512
  • McFarland CP, Lind SE. Thrombin Generation Biomarkers Decline With Parenteral Anticoagulation-An Overlooked Means of Anticoagulation Monitoring?. Clin Appl Thromb Hemost. 2018 Jul;24(5):708-717. PubMed PMID: 29439639
  • Beyer JT, Lind SE, Fisher S, Trujillo TC, Wempe MF, Kiser TH. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. J Thromb Thrombolysis. 2020 Feb;49(2):259-267. PubMed PMID: 31559512
  • Lind SE. Phosphatidylserine is an overlooked mediator of COVID-19 thromboinflammation. Heliyon. 2021 Jan;7(1):e06033. PubMed PMID: 33495740
  • George G, Friedman KD, Curtis BR, Lind SE. Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination. Am J Hematol. 2021 Aug 1;96(8):E301-E303. PubMed PMID: 33989437

Practice Locations

UCHealth Hematology Clinic - Anschutz Medical Campus
1665 Aurora Ct
2nd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

Hospital Affiliation
  • University of Colorado Hospital

Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (1979)
  • Medical Oncology, Board Certification (1981)
  • Hematology, Board Certification (1982, 2015)
  • Blood Banking / Transfusion Medicine, Board Certification (2007)
Conditions & Treatments
  • Blood / Lymphatic System
  • Blood / Lymphatic System - Blood Disorders
  • Cancers
  • Cancers - Leukemia (Adult Chronic)
  • Cancers - Lymphoma
  • Cancers - Myeloma
  • Blood / Lymphatic System - Bleeding Disorders
  • Blood / Lymphatic System - Clotting Disorders
Clinical Interests
I am interested in all aspects of hematology, including disorders of red blood cells, white blood cells, lymph nodes, platelets, bleeding and clottign disorders as well as cancers affecting the blood and lymph nodes.